What is the official website of Novartis España ?

The official website of Novartis España is https://www.novartis.es/.

What is Novartis España's cybersecurity risk score?

Novartis España has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis España experienced?

According to Rankiteo, Novartis España currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis España been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis España has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis España have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis España is not certified under SOC 2 Type 1.

Does Novartis España have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis España does not hold a SOC 2 Type 2 certification.

Does Novartis España comply with GDPR ?

According to Rankiteo, Novartis España is not listed as GDPR compliant.

Does Novartis España have PCI DSS certification ?

According to Rankiteo, Novartis España does not currently maintain PCI DSS compliance.

Does Novartis España comply with HIPAA ?

According to Rankiteo, Novartis España is not compliant with HIPAA regulations.

Does Novartis España have ISO 27001 certification ?

According to Rankiteo,Novartis España is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis España operate in ?

Novartis España operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis España have ?

Novartis España employs approximately 338 people worldwide.

Does Novartis España own any subsidiaries ?

Novartis España presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis España have ?

Novartis España's official LinkedIn profile has approximately 75,902 followers.

What is the NAICS classification code for Novartis España ?

Novartis España is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis España have a Crunchbase profile ?

No, Novartis España does not have a profile on Crunchbase.

Does Novartis España have a LinkedIn profile ?

Yes, Novartis España maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-espa-a.

How many cybersecurity incidents has Novartis España experienced ?

As of June 21, 2026, Rankiteo reports that Novartis España has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis España have ?

Novartis España has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis España faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis España

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Novartis España Vendor Cyber Rating & Cyber Score

novartis.es

Add Your Compliance Badge

Novartis está reimaginando la medicina con el fin de mejorar y prolongar la vida de las personas. Como compañía líder mundial en desarrollo de medicamentos, utilizamos la innovación basada en la ciencia y las tecnologías digitales para crear tratamientos transformadores en áreas con necesidades médicas importantes. En nuestra misión por descubrir nuevos medicamentos, nos situamos entre las mejores compañías a nivel mundial en términos de inversión en investigación y desarrollo. Los productos de Novartis llegan a más de 800 millones de personas a nivel global y nos esforzamos en encontrar soluciones innovadoras para expandir el acceso a nuestros tratamientos. Más de 110.000 personas de 142 nacionalidades distintas trabajan en Novartis en

Novartis España A.I CyberSecurity Scoring

Scoring History

Novartis España

Novartis España CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis España

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis España Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis España

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis España in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis España in 2026.

Incident Types Novartis España vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis España in 2026.

Incident History - Novartis España (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis España Subsidiaries

Novartis España

Pharmaceutical Manufacturing

Website: https://www.novartis.es/

Company Size: 338

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Loading…

Novartis España Similar Companies

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

Novartis España CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 31, 2024 07:00 AM

Jesús Ponce, Novartis Spain CEO, at Esade Matins: “We’re committed to transformative innovation”

The CEO underlined his company's commitment to Spain where it now has 1495 employees and a 2023 year-end turnover of €1.12 billion.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56355

SUMMARY

GNU Savannah Administration Savane through 3.17 uses untrusted data as part of authorization.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-56347

SUMMARY

AVideo TopMenu plugin through version 26.0 contains a stored cross-site scripting vulnerability in menu item rendering due to missing output encoding of icon classes, URLs, and text labels. Attackers can inject malicious JavaScript through unescaped menu item fields that execute for all site visitors, potentially stealing session cookies or performing unauthorized actions.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.8

REFERENCES

CVE-2026-56346

SUMMARY

AVideo through version 25.0 contains an authentication bypass vulnerability in the decryptMessage.json.php endpoint that allows unauthenticated users to decrypt PGP messages. Remote attackers can submit private keys, ciphertext, and passphrases to perform server-side decryption without credentials, exposing key material to logs and enabling resource exhaustion attacks.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-56345

SUMMARY

AVideo through 29.0 contains an authorization bypass vulnerability in the Meet plugin's uploadRecordedVideo.json.php endpoint that derives the target users_id from the uploaded filename without verification. An attacker with knowledge of the Meet shared secret can craft a malicious file upload with a filename containing an arbitrary users_id to invoke passwordless User->login() and establish an authenticated session as any user including admin. Attackers can obtain the Meet shared secret through path-traversal vulnerabilities or timing attacks against checkToken.json.php, then POST a crafted file to uploadRecordedVideo.json.php with a filename like '1-anything.mp4' to hijack admin sessions and gain full account takeover.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.2

REFERENCES

CVE-2026-56342

SUMMARY

AVideo through version 27.0 contains a server-side request forgery vulnerability in plugin/Live/test.php that allows authenticated administrators to read arbitrary URLs via the statsURL parameter, which lacks isSSRFSafeURL() validation and accepts requests to private IP ranges and cloud metadata endpoints. Attackers can exploit this by crafting requests to internal services, cloud metadata endpoints like 169.254.169.254, and localhost to retrieve sensitive information including IAM credentials, internal service responses, and network configuration details.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…